Landscape → CNS

Migraine

346 clinical trials

84 active

346 total (since 2015)

Phase 1 Active

44 total

Phase 2 Active

83 total

Phase 3 Active

156 total

Phase 4 Active

80 total

Top Sponsors (Industry)

Sorted by active Active Done Failed

AbbVie 10 18 3

Pfizer 6 18 2

H. Lundbeck A/S 5 11 1

Eli Lilly 4 22 0

Ipsen 3 0 0

Theranica 2 1 0

Merz Therapeutics GmbH 2 0 0

Amgen 1 14 1

Sichuan Purity Pharmaceutical Technology Co., Ltd. 1 1 0

Upsher-Smith Laboratories 1 1 0

IntraBio Inc 1 0 0

Alasht Pharmed 1 0 0

Dr George Medvedev 1 0 0

Teva Branded Pharmaceutical Products R&D, Inc. 0 8 0

Novartis 0 6 2

NCT05125302 RECRUITING

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

AbbVie n=1,059

NCT06616194 RECRUITING

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Pfizer n=200

NCT07018713 RECRUITING

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

Merz Therapeutics GmbH n=780

NCT07018700 RECRUITING

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

Merz Therapeutics GmbH n=990

NCT04616326 ACTIVE NOT RECRUITING

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Eli Lilly and Company n=312

NCT06047457 ACTIVE NOT RECRUITING

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

Ipsen n=751

NCT06047444 ACTIVE NOT RECRUITING

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

Ipsen n=759

NCT06241313 RECRUITING

Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

AbbVie n=1,300

NCT04965675 RECRUITING

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

H. Lundbeck A/S n=285

NCT05164172 RECRUITING

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

H. Lundbeck A/S n=600

NCT06810505 RECRUITING

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

AbbVie n=420

NCT05711394 RECRUITING

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

AbbVie n=450

NCT05156398 RECRUITING

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Pfizer n=640

NCT04743141 RECRUITING

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Pfizer n=600

NCT06641466 RECRUITING

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Pfizer n=723

NCT04649242 RECRUITING

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Pfizer n=2,100

NCT03432286 ACTIVE NOT RECRUITING

A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Eli Lilly and Company n=533

NCT06904287 RECRUITING

Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines

Wake Forest University Health Sciences n=100

NCT05897320 RECRUITING

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

H. Lundbeck A/S n=315

NCT03836040 ACTIVE NOT RECRUITING

Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

Amgen n=457

NCT06417775 RECRUITING

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

AbbVie n=496

NCT07221292 NOT YET RECRUITING

Pivotal Study of N-acetyl-L-leucine for CACNA1A

IntraBio Inc n=60

NCT04396574 RECRUITING

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Eli Lilly and Company n=1,000

NCT04396236 RECRUITING

A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Eli Lilly and Company n=1,633

NCT06806293 RECRUITING

Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

AbbVie n=430

NCT07147972 NOT YET RECRUITING

Comparative Study of Nutraceuticals vs. Conventional Prophylactic Therapy in the Management of Migraine

Fayoum University n=100

NCT05707949 ENROLLING BY INVITATION

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine

AbbVie n=650

NCT04069897 ACTIVE NOT RECRUITING

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine

St. Olavs Hospital n=170

NCT05127954 ENROLLING BY INVITATION

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

AbbVie n=1,200

NCT07040813 RECRUITING

The Nordic Chronic Migraine Trial of CGRP Monoclonal Antibody and Onabotulinumtoxin A Dual Therapy Compared to CGRP mAbs Monotherapy

Oslo University Hospital n=450

NCT05748483 ACTIVE NOT RECRUITING

Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine

AbbVie n=545

NCT05598723 RECRUITING

BOTOX® vs. XEOMIN® for Chronic Migraine

Naval Medical Center Camp Lejeune n=128

NCT04151472 RECRUITING

Idebenone for the Preventive Treatment of Migraine

Second Affiliated Hospital, School of Medicine, Zhejiang University n=180

NCT06937385 NOT YET RECRUITING

0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment

HCA Florida North Florida Hospital n=100

NCT04946734 ACTIVE NOT RECRUITING

Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine

Guangdong Provincial People's Hospital n=440

NCT05484349 RECRUITING

TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME）

Second Affiliated Hospital, School of Medicine, Zhejiang University n=189

NCT05741775 RECRUITING

Physiotherapy Intervention for Migraine Symptoms

Universiti Tunku Abdul Rahman n=87

NCT06428838 NOT YET RECRUITING

Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context

Dr George Medvedev n=102

NCT06347497 RECRUITING

Zonisamide Versus Topiramate in Migraine

Kafrelsheikh University n=600

NCT06361446 RECRUITING

Zonisamide Versus Propranolol in Migraine

Kafrelsheikh University n=600

NCT06243692 RECRUITING

Lacosamide Versus Topiramate in Migraine

Kafrelsheikh University n=600

NCT04530110 COMPLETED

A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

Teva Branded Pharmaceutical Products R&D LLC n=506

NCT04163185 COMPLETED

Initiating Early Control of Migraine Pain and Associated Symptoms

Axsome Therapeutics, Inc. n=302

NCT03832998 COMPLETED

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

Amgen n=284

NCT05064371 COMPLETED

Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

H. Lundbeck A/S n=160

NCT05810038 COMPLETED

A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

Pfizer n=787

NCT04921384 COMPLETED

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

H. Lundbeck A/S n=981

NCT06103734 WITHDRAWN

A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants

Pfizer

NCT04464707 COMPLETED

A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age

Teva Branded Pharmaceutical Products R&D, Inc. n=292

NCT04686136 COMPLETED

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

AbbVie n=596

NCT05028569 TERMINATED

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

AbbVie n=775

NCT05550207 COMPLETED

Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)

Axsome Therapeutics, Inc. n=100

NCT05458011 COMPLETED

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine

Teva Branded Pharmaceutical Products R&D, Inc. n=365

NCT05399485 COMPLETED

Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)

Pfizer n=496

NCT03867201 COMPLETED

Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients

Novartis Pharmaceuticals n=557

NCT04726592 TERMINATED

Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room

Assistance Publique - Hôpitaux de Paris n=323

NCT05989048 COMPLETED

A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

Pfizer n=1,414

NCT04437433 COMPLETED

A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine

AbbVie n=186

NCT05641363 COMPLETED

Comparison of Ketorolac at Three Doses in Children With Acute Pain

Hamilton Health Sciences Corporation n=171

NCT04458857 COMPLETED

A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age

Teva Branded Pharmaceutical Products R&D, Inc. n=235

NCT05216263 COMPLETED

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

AbbVie n=75

NCT02725554 WITHDRAWN

Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine

Curonix LLC

NCT03526874 COMPLETED

Occipital Blocks for Acute Migraine

Children's Hospital of Philadelphia n=63

NCT04804033 TERMINATED

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Pfizer n=1,753

NCT05861427 COMPLETED

Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine

AbbVie n=523

NCT05102591 COMPLETED

A Pilot Clinical Trial of a New Neuromodulation Device for Acute Attacks of Migraine in Children and Adolescents

University of Calgary n=22

NCT05399459 COMPLETED

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Pfizer n=897

NCT04989413 TERMINATED

Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine -

Hospital Israelita Albert Einstein n=110

NCT05371652 COMPLETED

A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

Pfizer n=241

NCT04384367 COMPLETED

Efficacy and Safety of Rizatriptan-Naproxen (10/550 Mg) in the Acute Treatment of Migraine

Eurofarma Laboratorios S.A. n=2,068

NCT06004388 COMPLETED

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Click Therapeutics, Inc. n=110

NCT05967442 COMPLETED

Magnesium Versus Prochlorperazine Versus Metoclopramide for Migraines

Wake Forest University Health Sciences n=157

NCT06248931 COMPLETED

Valproate Versus Topiramate in Migraine

Kafrelsheikh University n=600

NCT03732638 COMPLETED

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

Pfizer n=1,590

NCT04698525 COMPLETED

Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.

Universidad Autonoma de San Luis Potosí n=33

NCT05851781 COMPLETED

Lacosamide Versus Propranolol in Migraine

Kafrelsheikh University n=600

NCT05632133 COMPLETED

The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients

Kafrelsheikh University n=200

NCT03812224 COMPLETED

A Controlled Trial of Erenumab in Migraine Prevention

Amgen n=261

NCT04349176 TERMINATED

Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units?

United States Naval Medical Center, San Diego n=35

NCT03337620 COMPLETED

Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine

Tian Medical Inc. n=174

NCT04574362 COMPLETED

Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine

Pfizer n=1,648

NCT04940390 COMPLETED

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

Satsuma Pharmaceuticals, Inc. n=1,591

NCT05046522 COMPLETED

A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.

RDC Clinical Pty Ltd n=80

NCT04068051 COMPLETED

Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)

Axsome Therapeutics, Inc. n=706

NCT04418765 COMPLETED

A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments

H. Lundbeck A/S n=892

NCT03872453 COMPLETED

Acute Treatment Trial in Adult Subjects With Migraines

Pfizer n=2,154

NCT04740827 COMPLETED

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

Allergan n=315

NCT03896009 COMPLETED

Maximizing Outcomes in Treating Acute Migraine

Axsome Therapeutics, Inc. n=1,594

NCT03338920 TERMINATED

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

Currax Pharmaceuticals n=159

NCT04406649 COMPLETED

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

Satsuma Pharmaceuticals, Inc. n=482

NCT03901482 COMPLETED

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

Satsuma Pharmaceuticals, Inc. n=1,201

NCT04492020 COMPLETED

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

AbbVie n=518

NCT04829747 COMPLETED

Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic Migraine

Allergan n=3

NCT04408794 COMPLETED

Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

Pfizer n=974

NCT04571060 COMPLETED

Randomized Trial in Adult Participants With Acute Migraines

Pfizer n=1,978

NCT03963232 COMPLETED

A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine

Eli Lilly and Company n=520

NCT03303105 COMPLETED

Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine

Otsuka Pharmaceutical Co., Ltd. n=50

NCT03235479 COMPLETED

Safety and Efficacy Study in Adult Subjects With Acute Migraines

Pfizer n=1,485

NCT03266588 COMPLETED

Open Label Safety Study in Acute Treatment of Migraine

Pfizer n=3,019

NCT03237845 COMPLETED

Safety and Efficacy in Adult Subjects With Acute Migraines

Pfizer n=1,499

NCT03461757 COMPLETED

Trial in Adult Subjects With Acute Migraines

Pfizer n=1,811

NCT03855137 COMPLETED

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Allergan n=778

NCT03009019 COMPLETED

Efficacy, Tolerability, and Safety of DFN-15

BioDelivery Sciences International n=631

NCT03006276 COMPLETED

Efficacy, Tolerability, and Safety Study of DFN-15

BioDelivery Sciences International n=622

NCT04772742 COMPLETED

Eptinezumab in Adults With Migraine and Medication Overuse Headache

H. Lundbeck A/S n=193

NCT02483585 COMPLETED

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention

Amgen n=577

NCT02456740 COMPLETED

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

Amgen n=955

NCT03670810 COMPLETED

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Eli Lilly and Company n=1,633

NCT02614261 COMPLETED

Evaluation of Galcanezumab in the Prevention of Chronic Migraine

Eli Lilly and Company n=1,117

NCT03939312 COMPLETED

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

Allergan n=685

NCT03096834 COMPLETED

A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

Novartis Pharmaceuticals n=246

NCT02358681 COMPLETED

Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children

Columbia University n=59

NCT02629861 COMPLETED

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

Teva Branded Pharmaceutical Products R&D, Inc. n=875

NCT02621931 COMPLETED

Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine

Teva Branded Pharmaceutical Products R&D, Inc. n=1,130

NCT02638103 COMPLETED

Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine

Teva Branded Pharmaceutical Products R&D, Inc. n=1,890

NCT03308968 COMPLETED

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine

Teva Branded Pharmaceutical Products R&D, Inc. n=838

NCT04355117 COMPLETED

A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients

Otsuka Pharmaceutical Co., Ltd. n=71

NCT03333109 COMPLETED

Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients

Novartis Pharmaceuticals n=900

NCT04152083 COMPLETED

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

H. Lundbeck A/S n=485

NCT03303092 COMPLETED

Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine

Otsuka Pharmaceutical Co., Ltd. n=357

NCT03777059 COMPLETED

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

Allergan n=910

NCT03700320 COMPLETED

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Allergan n=744

NCT03303079 COMPLETED

Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine

Otsuka Pharmaceutical Co., Ltd. n=571

NCT03185143 COMPLETED

Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

Allodynic Therapeutics, Inc n=36

NCT04218162 COMPLETED

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean

IlDong Pharmaceutical Co Ltd n=294

NCT03557333 COMPLETED

Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)

Impel Pharmaceuticals n=360

NCT03275922 COMPLETED

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

Impax Laboratories, LLC n=374

NCT02322333 COMPLETED

MLD10 in the Prevention of Migraine in Adults

Pharmalyte Solutions LLC n=157

NCT02959190 COMPLETED

A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine

Eli Lilly and Company n=311

NCT02565186 COMPLETED

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

Eli Lilly and Company n=2,171

NCT03282227 COMPLETED

A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

Zosano Pharma Corporation n=342

NCT02665273 COMPLETED

Greater Occipital Nerve Block With Bupivacaine for Acute Migraine

Montefiore Medical Center n=28

NCT03559257 COMPLETED

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

Eli Lilly and Company n=463

NCT02593097 COMPLETED

Metformin for the Prevention of Episodic Migraine (MPEM)

Mayo Clinic n=34

NCT02614183 COMPLETED

Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study

Eli Lilly and Company n=862

NCT02614287 COMPLETED

A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura

Eli Lilly and Company n=270

NCT02614196 COMPLETED

Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study

Eli Lilly and Company n=986

NCT02974153 COMPLETED

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

Alder Biopharmaceuticals, Inc. n=1,121

NCT04114630 WITHDRAWN

Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab

Novartis Pharmaceuticals

NCT02559895 COMPLETED

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

Alder Biopharmaceuticals, Inc. n=898

NCT02985398 COMPLETED

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

Alder Biopharmaceuticals, Inc. n=128

NCT02439320 COMPLETED

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:

Eli Lilly and Company n=2,231

NCT02794441 COMPLETED

Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in the Pediatric Emergency Department

Children's Hospital of Eastern Ontario n=12

NCT02605174 COMPLETED

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

Eli Lilly and Company n=3,005

NCT02873221 COMPLETED

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Allergan n=1,254

NCT03022838 TERMINATED

The Effects of Caffeine Withdrawal on Migraine

Nordlandssykehuset HF n=10

NCT02933060 COMPLETED

Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache

The Cooper Health System n=50

NCT02582996 SUSPENDED

Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks

Ache Laboratorios Farmaceuticos S.A. n=336

NCT02706015 WITHDRAWN

Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks

Ache Laboratorios Farmaceuticos S.A.

NCT02867709 COMPLETED

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

Allergan n=1,686

NCT02828020 COMPLETED

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

Allergan n=1,672

NCT02848326 COMPLETED

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Allergan n=834

NCT02569853 COMPLETED

DFN-11 Injection in Episodic Migraine With or Without Aura

Dr. Reddy's Laboratories Limited n=268

NCT02745392 COMPLETED

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

Zosano Pharma Corporation n=365

NCT03193359 WITHDRAWN

Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine

Allergan

NCT03193346 WITHDRAWN

BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine

Allergan

NCT06625060 RECRUITING

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

Ipsen

NCT06248671 RECRUITING

Prophylactic Treatment With Atorvastatin for Episodic Migraine.

St. Olavs Hospital

NCT06323928 ACTIVE NOT RECRUITING

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

H. Lundbeck A/S

NCT07304518 RECRUITING

Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults

Sichuan Purity Pharmaceutical Technology Co., Ltd.

NCT07361549 NOT YET RECRUITING

Localized Injection of Lidocaine Via the Middle Meningeal Artery for Intractable Headache Treatment

Daniel A Tonetti, MD

NCT06602479 RECRUITING

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

AbbVie

NCT04063540 RECRUITING

Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura

Centre Hospitalier Universitaire de Nice

NCT07072910 RECRUITING

Cabergoline for Episodic Migraine

Aarhus University Hospital

NCT07061847 RECRUITING

Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines

Northwell Health

NCT04567355 RECRUITING

Migraine Manager (R01)

Children's Hospital Medical Center, Cincinnati

NCT06485336 RECRUITING

Prophylactic Treatment With Atorvastatin for Chronic Migraine (ChronicStatinMig)

St. Olavs Hospital

NCT06992674 ACTIVE NOT RECRUITING

The R-E-V-I-V-A-L Study

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT05337033 RECRUITING

Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial

University of Manitoba

NCT06748664 NOT YET RECRUITING

A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment

Second Affiliated Hospital, School of Medicine, Zhejiang University

NCT05734625 RECRUITING

Efficacy of Nerve Blocks for Episodic Migraine

Mayo Clinic

NCT06716944 ENROLLING BY INVITATION

Self-acupuncture for Migraines Feasibility Study

University of West London

NCT04930887 RECRUITING

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

Stanford University

NCT03972124 NOT YET RECRUITING

Cannabis for the Prophylactic Treatment of Migraine

University of Calgary

NCT06603623 COMPLETED

Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

Biohaven Therapeutics Ltd.

NCT06083571 TERMINATED

Intranasal Ketorolac Trial

Washington University School of Medicine

NCT05685225 WITHDRAWN

Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial

Allodynic Therapeutics, Inc

NCT07116499 TERMINATED

A Study of K-645 in the Treatment of Multiple Migraine Attacks

Kallyope Inc.

NCT05846373 COMPLETED

Effect of Nicotinic Acid as Add on Therapy in Patients Receiving β Blocker for Prophylaxis of Moderate to Severe Migraine

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

NCT06728553 COMPLETED

Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

Manistee Therapeutics

NCT06848075 COMPLETED

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

Kallyope Inc.

NCT03472092 COMPLETED

Mind and Body Approaches to Pain Reduction in Youth With Migraine

Children's Hospital Medical Center, Cincinnati

NCT04574713 COMPLETED

Candesartan for Migraine Prevention:

St. Olavs Hospital

NCT05679908 COMPLETED

A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine

Tonix Pharmaceuticals, Inc.

NCT04417361 COMPLETED

Galcanezumab for Vestibular Migraine

University of California, San Francisco

NCT05016661 TERMINATED

Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

AEON Biopharma, Inc.

NCT04845178 COMPLETED

Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

AEON Biopharma, Inc.

NCT03578354 WITHDRAWN

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

Massachusetts Eye and Ear Infirmary

NCT02266329 COMPLETED

Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin

VA Office of Research and Development

NCT03844412 COMPLETED

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

Duke University

NCT05427630 SUSPENDED

Dose-Ranging Trial of Inhaled Cannabis for Acute Migraine Treatment

University of California, San Diego

NCT03194555 COMPLETED

The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination

Allodynic Therapeutics, Inc

NCT05133323 COMPLETED

A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

H. Lundbeck A/S

NCT04437199 COMPLETED

Tricaprilin Phase 2 Pilot Study in Migraine

Cerecin

NCT06245902 COMPLETED

An Acute Migraine Factorial Study

Allodynic Therapeutics, Inc

NCT03543254 COMPLETED

"Follow the Sutures". A New Procedure for Injection of Botulinum Toxin for Chronic Migraine

Norwegian University of Science and Technology

NCT04498910 COMPLETED

A Study of LY3451838 in Participants With Migraine

Eli Lilly and Company

NCT03055767 COMPLETED

Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population

University of California, Irvine

NCT03150797 TERMINATED

Melatonin for Adolescent Migraine Prevention Study

Amy Gelfand

NCT04992494 COMPLETED

Treatment for Migraine and Mood (Team-M)

NYU Langone Health

NCT04360044 COMPLETED

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

University of California, San Diego

NCT02630459 COMPLETED

A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention

Amgen

NCT03488563 COMPLETED

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

AOBiome LLC

NCT04334408 WITHDRAWN

Safety and Efficacy of Fremanezumab for Migraine in Adult CADASIL

Mayo Clinic

NCT03885154 TERMINATED

Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

Kimberly S Jones

NCT02344316 COMPLETED

Bringing Relief to Adolescents Naturally Using Melatonin for Migraine

Amy Gelfand

NCT04102995 COMPLETED

A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine

Asarina Pharma

NCT03597529 COMPLETED

CHOCOlate MeLatonin for AdolescenT MigrainE

Amy Gelfand

NCT03962738 COMPLETED

A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine

Eli Lilly and Company

NCT04153409 COMPLETED

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

Lateral Pharma Pty Ltd

NCT02959177 COMPLETED

A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine

Eli Lilly and Company

NCT03061734 COMPLETED

Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine

Allodynic Therapeutics, Inc

NCT02856802 COMPLETED

An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

Upsher-Smith Laboratories

NCT04466826 WITHDRAWN

Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients

Washington University School of Medicine

NCT04578782 COMPLETED

Efficacy of OnabotulinumtoxinA in Migraine

IRCCS National Neurological Institute "C. Mondino" Foundation

NCT03108469 COMPLETED

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine

Smith, Timothy R., M.D.

NCT03238781 COMPLETED

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

Amgen

NCT03280342 WITHDRAWN

Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine

University of Minnesota

NCT03877718 COMPLETED

A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain

Charleston Laboratories, Inc

NCT03836664 COMPLETED

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

University of Kansas Medical Center

NCT03472378 COMPLETED

Can DFN-15 Terminate Migraine With Allodynia?

Hartford Hospital

NCT02571049 COMPLETED

Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine

Dr. Reddy's Laboratories Limited

NCT02472418 COMPLETED

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

Dr. Reddy's Laboratories Limited

NCT01617941 WITHDRAWN

A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention

Novartis Pharmaceuticals

NCT02259075 COMPLETED

Botox Injection in Treatment of Chronic Migraine

Norwegian University of Science and Technology

NCT06995729 RECRUITING

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

Pfizer

NCT03511846 ENROLLING BY INVITATION

Pain Biomarker Study

The University of Texas Health Science Center, Houston

NCT07068815 NOT YET RECRUITING

Efficacy and Mechanism of Fu's Subcutaneous Needling Treatment for Migraine Without Aura

Guangzhou University of Chinese Medicine

NCT07016516 COMPLETED

A Study to Learn About PRT-064040 Nasal Spray in Healthy Adult Subjects

Sichuan Purity Pharmaceutical Technology Co., Ltd.

NCT06462781 COMPLETED

Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1

The Cooper Health System

NCT06578585 COMPLETED

A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

H. Lundbeck A/S

NCT05477095 COMPLETED

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants

Vaxxinity, Inc.

NCT04580238 WITHDRAWN

Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache

University of Alberta

NCT03499119 COMPLETED

AMG 334 20160172 Pediatric Migraine PK Study.

Amgen

NCT04218539 COMPLETED

Repeat Dosing of Psilocybin in Migraine Headache

Yale University

NCT06180070 COMPLETED

Bioequivalence Study to Compare Ibuprofen/ Paracetamol Tablets (200mg Ibuprofen/ 500mg Paracetamol) Versus Nuromol® Tablets (200mg Ibuprofen/ 500mg Paracetamol)

Humanis Saglık Anonim Sirketi

NCT03341689 COMPLETED

Psilocybin for the Treatment of Migraine Headache

Yale University

NCT04537429 COMPLETED

A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

H. Lundbeck A/S

NCT05304910 COMPLETED

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

H. Lundbeck A/S

NCT03229798 COMPLETED

Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)

Sorrento Therapeutics, Inc.

NCT03335163 COMPLETED

The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users

University of Colorado, Denver

NCT04818515 COMPLETED

Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

AbbVie

NCT05337254 COMPLETED

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Satsuma Pharmaceuticals, Inc.

NCT03978403 COMPLETED

A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers

Zosano Pharma Corporation

NCT04201080 TERMINATED

A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250

Trevena Inc.

NCT04969497 COMPLETED

Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers

Zosano Pharma Corporation

NCT03806595 COMPLETED

A Pilot Study of Intranasal Lidocaine in Acute Management of Pediatric Migraine

University of British Columbia

NCT04179474 COMPLETED

Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

Allergan

NCT04401137 COMPLETED

The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects

SK Chemicals Co., Ltd.

NCT04197349 COMPLETED

Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman

H. Lundbeck A/S

NCT03988088 COMPLETED

A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

Eli Lilly and Company

NCT04353505 WITHDRAWN

Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache

Weill Medical College of Cornell University

NCT03708744 COMPLETED

A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers

Zosano Pharma Corporation

NCT03012334 COMPLETED

The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants

Eli Lilly and Company

NCT03009162 COMPLETED

Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function

Eli Lilly and Company

NCT03076970 COMPLETED

Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants

Eli Lilly and Company

NCT03247790 COMPLETED

A Study of Lasmiditan in Participants With Migraine

Eli Lilly and Company

NCT03040479 COMPLETED

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

Eli Lilly and Company

NCT03874832 COMPLETED

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Satsuma Pharmaceuticals, Inc.

NCT02542605 COMPLETED

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

Amgen

NCT03401346 COMPLETED

Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

Impel Pharmaceuticals

NCT02792517 COMPLETED

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

Amgen

NCT02905227 COMPLETED

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

Acorda Therapeutics

NCT03282838 COMPLETED

Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects

Dr. Reddy's Laboratories Limited

NCT02609945 COMPLETED

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

Acorda Therapeutics

NCT02411513 COMPLETED

Acute Treatment of Migraine Using the CEFALY Device

Cefaly Technology

NCT06173661 ACTIVE NOT RECRUITING

Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45

Brigham and Women's Hospital

NCT06972056 RECRUITING

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

Mayo Clinic

NCT06701526 RECRUITING

A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

H. Lundbeck A/S

NCT07336056 ACTIVE NOT RECRUITING

Nerivio Efficacy Under High-Frequency Use

Theranica

NCT07336420 ENROLLING BY INVITATION

Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment

Theranica

NCT07301008 RECRUITING

Rimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US

Medstar Health Research Institute

NCT06473597 RECRUITING

A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache

Antonios Likourezos

NCT06401642 RECRUITING

Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

Mayo Clinic

NCT02670161 ENROLLING BY INVITATION

Quality Improvement and Practice Based Research in Neurology Using the EMR

Endeavor Health

NCT07100496 NOT YET RECRUITING

Evaluation of MIG-SPRAY Treatment on Migraine

University Hospital, Clermont-Ferrand

NCT07093138 RECRUITING

Evaluation of Efficacy and Safety of Topical Cannabidiol (Canvert-M Produced by Alasht Pharmed co. Iran) in the Treatment of Migraine Attacks

Alasht Pharmed

NCT06985342 RECRUITING

Acute Migraine Treatment in the ED With Gepants

Icahn School of Medicine at Mount Sinai

NCT06786650 ACTIVE NOT RECRUITING

Comparision of the Analgesic Effects of Intravenous Ibuprofen and Tenoxicam in Acute Migraine Attack

Haydarpasa Numune Training and Research Hospital

NCT07022496 RECRUITING

Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals

Ain Shams University

NCT04748601 RECRUITING

Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

Upsher-Smith Laboratories

NCT04925414 RECRUITING

Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)

Centre Hospitalier Universitaire de Nice

NCT06509503 RECRUITING

Impact of Combined Oral Contraceptive Pills on Migraine

Kafrelsheikh University

NCT05724771 ACTIVE NOT RECRUITING

COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study

Chicago Headache Center & Research Institute

NCT05503082 ACTIVE NOT RECRUITING

Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies

Chicago Headache Center & Research Institute

NCT06499116 NOT YET RECRUITING

Comparison of the Effectiveness of First-line Preventive Treatment of Migraine in Primary Care

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

NCT06485726 RECRUITING

Valproate Versus Propranolol in Migraine

Kafrelsheikh University

NCT06432127 NOT YET RECRUITING

Role of Ultrasound Guide Greater Occipital Nerve Block at Second Cervical Vertebra in Migraine Headache Prophylaxis

Mahidol University

NCT04693533 TERMINATED

Fremanezumab, Migraine and Sleep

Beth Israel Deaconess Medical Center

NCT05452239 COMPLETED

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

H. Lundbeck A/S

NCT04271202 COMPLETED

Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

Beth Israel Deaconess Medical Center

NCT04050293 TERMINATED

Therapy for Migraine Prevention in Children 6-11 Years of Age

Supernus Pharmaceuticals, Inc.

NCT05217927 COMPLETED

Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

Pfizer

NCT05211154 TERMINATED

Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine

Danish Headache Center

NCT03971071 COMPLETED

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

Amgen

NCT05207865 COMPLETED

Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

Pfizer

NCT06976723 COMPLETED

Nerivio Efficacy by Time of Treatment Onset

Theranica

NCT05509400 COMPLETED

Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use

Pfizer

NCT05518123 COMPLETED

Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

Pfizer

NCT05214001 TERMINATED

Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine

Messoud Ashina, MD

NCT03381261 COMPLETED

(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist

Massachusetts General Hospital

NCT05101837 COMPLETED

Feasibility and Effectiveness of a Specific App to Delivery Mindfulness Sessions

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

NCT03671681 COMPLETED

Mindfulness Therapy for Chronic Migraine

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

NCT04410536 COMPLETED

Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

NCT04389372 COMPLETED

Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients with Chronic Migraine and Medication Overuse

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

NCT04084314 COMPLETED

Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

Novartis Pharmaceuticals

NCT05264129 COMPLETED

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

AbbVie

NCT04825678 COMPLETED

A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

Amgen

NCT04252742 COMPLETED

Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine

Amgen

NCT05127486 COMPLETED

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Eli Lilly and Company

NCT04265755 COMPLETED

Biomarker and Genetic Predictors of Erenumab Treatment Response

Amgen

NCT05284019 TERMINATED

Real World Effectiveness of Eptinezumab in Participants With Migraine

H. Lundbeck A/S

NCT04112823 COMPLETED

Dexamethasone for Migraine - Dose Comparison

Montefiore Medical Center

NCT03773562 COMPLETED

Imaging the Migraine Brain Pre- and Post-Erenumab

Mayo Clinic

NCT03927144 COMPLETED

Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

Amgen

NCT04041284 COMPLETED

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Teva Branded Pharmaceutical Products R&D, Inc.

NCT05492695 TERMINATED

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

Diamond Headache Clinic

NCT04064814 COMPLETED

Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population

All India Institute of Medical Sciences, Bhubaneswar

NCT05679765 COMPLETED

Efficacy of GONB in Patients of Migraine

Pain Medicine Department

NCT04465357 COMPLETED

Efficacy of Erenumab on Functional Impact of Migraine

Merle Diamond

NCT03912337 TERMINATED

Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

Amgen

NCT03698409 COMPLETED

Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine.

State University of New York - Upstate Medical University

NCT04461795 COMPLETED

Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

David True

NCT03919045 TERMINATED

Saline Injections for Prophylactic Treatment of Chronic Migraine

Göteborg University

NCT04294147 COMPLETED

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

Eli Lilly and Company

NCT04533568 COMPLETED

Ibuprofen in Migraine Patients

Kecioren Education and Training Hospital

NCT03159000 WITHDRAWN

A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks

Thomas Jefferson University

NCT03828539 COMPLETED

Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine

Novartis Pharmaceuticals

NCT03666663 COMPLETED

Sphenopalatine Ganglion Blocks RCT

University of California, San Francisco

NCT03269435 COMPLETED

Greater Occipital Nerve Block Versus Metoclopramide

Montefiore Medical Center

NCT03977649 COMPLETED

A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients

Novartis Pharmaceuticals

NCT04491474 COMPLETED

Comparison of Great Occipital Nerve and Supraorbital Nerve Blockade Methods at Treatment of Acute Migraine Attack in the Emergency Department

Dr. Lutfi Kirdar Kartal Training and Research Hospital

NCT03689361 COMPLETED

Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase.

University Hospital, Toulouse

NCT02747940 COMPLETED

Neurologic Signatures of Chronic Pain Disorders

Taipei Veterans General Hospital, Taiwan

NCT04017741 COMPLETED

A Study Investigating the Efficacy of GON Blocks.

Barts & The London NHS Trust

NCT02945839 WITHDRAWN

Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department

NYU Langone Health

NCT02518464 COMPLETED

Ticagrelor Therapy for RefrACTORy Migraine Study

Columbia University

NCT03175900 COMPLETED

Effectiveness and Neural Mechanism of Naoan Dripping Pills for Migraine

Dongzhimen Hospital, Beijing

NCT02847494 COMPLETED

Corticosteroids for Acute Migraine in the Emergency Department

Montefiore Medical Center

NCT02389829 COMPLETED

Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine

Montefiore Medical Center

NCT03606356 COMPLETED

Sustained onabotulinumtoxinA Therapeutic Benefits in Patients With Chronic Migraine

Corfu Headache Clinic

NCT02578719 WITHDRAWN

Greater Occipital Nerve (GON) Block Effectivity in the Treatment of Chronic Migraine: 6 Months Follow up

Bozok University

NCT02747511 COMPLETED

IV Haloperidol for the Treatment of Headache in the ED

Western Michigan University School of Medicine

NCT02436499 COMPLETED

Chronic Migraine Treatment With Botulinum Toxin-A: an Investigation of Functional Magnetic Resonance Imaging Changes.

University of Manitoba

NCT02287376 COMPLETED

Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds

Depomed

NCT03145467 COMPLETED

Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine in Emergency Department

Pamukkale University

Data: ClinicalTrials.gov